HRS Aluglaze H1 FY27: PAT falls 73% YoY on margin squeeze despite 28% revenue growth

HRS Aluglaze's consolidated net profit for the half year ended September 2026 fell 73.4% year-on-year to ₹1.21 Cr (H1 FY26: ₹4.54 Cr), even as consolidated revenue grew 27.8% YoY to ₹33.65 Cr. The standalone entity shows the same pattern in a milder form — PAT down 57.8% YoY to ₹1.91 Cr on revenue up 19.8% to ₹31.56 Cr — and since there are no exceptional or extraordinary items in either period (confirmed in the statement), this is a clean, operating-level decline rather than a one-off distortion; raw and adjusted YoY PAT growth are therefore the same, both sharply negative. The margin bridge is squarely on costs. Consolidated net margin compressed to 3.6% from 17.2% a year ago, and PBT margin fell to 4.0% from 23.2%. Cost of materials net of the inventory-change adjustment rose to roughly 50.7% of standalone revenue from about 40.0% a year ago, and employee benefit expenses grew 54.6% YoY to ₹6.08 Cr (consolidated) even as other expenses rose 43.1% YoY — a cost run-up consistent with gearing up for new capacity ahead of matching revenue. The company's own notes point to why: the Rajoda assembly and glass-glazing line, originally scheduled for completion by July 2026, is now expected only by January 2027 (Note 6), a six-month slip that likely explains part of the elevated employee and overhead base without the corresponding output yet online. On top of this, consolidated figures are additionally dragged by subsidiary Geotrix Private Limited (67%-held) — group PBT of ₹1.34 Cr sits ₹1.05 Cr below standalone PBT of ₹2.39 Cr, with minority shareholders absorbing roughly ₹0.35 Cr of that loss, which is why the standalone-vs-consolidated PAT decline diverges by more than 15 percentage points (-57.8% vs -73.4%). There is no management guidance on record in our database and none is given in this filing or an accompanying press release — the company gives no formal forward outlook to measure this quarter against, so vs-guidance is unknown rather than a miss. A web search for Street/consensus estimates for this half-year turned up no credible brokerage coverage specific to this period (only prior FY26 full-year coverage), consistent with this being a recently SME-listed micro-cap with limited analyst tracking; vs-street is therefore also unknown rather than inferred. The quarter's other disclosed developments — the 14th AGM on September 30, 2026, and routine auditor appointments — are governance housekeeping and don't bear on the P&L. As a half-yearly (not quarterly) reporter under the SME listing exemption, HRS Aluglaze does not publish a true sequential quarter-on-quarter comparison; the prior half (H2 FY26, derived from full-year-minus-H1 figures) showed materially higher revenue (₹41.20 Cr) and PAT (₹5.68 Cr), but that comparison is not QoQ and is noted here only for context, not as the basis for the verdict. Going into H2 FY27, the read-through is that revenue growth is intact but profitability has not kept pace, with the Rajoda delay and subsidiary losses as the two concrete, numbered drags disclosed in this filing.